vive advisory group Information

vive advisory group works with Series A–B biopharma companies to strengthen asset value before it becomes constrained. Most biopharma assets don’t fail because the science is weak. They fail because they are not fully fundable—where data, IP, and commercial strategy do not align under investor scrutiny. vive partners with leadership teams before Phase III, before pivotal inflection points, and before the narrative becomes difficult to change. We focus on the decisions that shape asset value: • Positioning and differentiation • Evidence strategy and future relevance • Payer and market realities • External narrative across stakeholders • Strategic flexibility before Phase III Our role is to provide senior strategic clarity at the point where clinical, commercial, and investor considerations converge. vive operates as a selective, senior-led advisory partner to executive teams navigating financing, partnership, and pre-launch decisions. Designed to surface what matters—before it surfaces in diligence.